<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-29T09:59:09Z</responseDate><request verb="GetRecord" identifier="oai:publikationen.uni-tuebingen.de:10900/110762" metadataPrefix="mets">https://publikationen.uni-tuebingen.de/oai/request</request><GetRecord><record><header><identifier>oai:publikationen.uni-tuebingen.de:10900/110762</identifier><datestamp>2021-01-07T06:40:24Z</datestamp><setSpec>com_10900_42126</setSpec><setSpec>col_10900_42133</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_10900-110762" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:10900/110762">
<metsHdr CREATEDATE="2026-09-29T11:59:09Z">
<agent TYPE="ORGANIZATION" ROLE="CUSTODIAN">
<name>Publikationssystem UB Tuebingen</name>
</agent>
</metsHdr>
<dmdSec ID="DMD_10900_110762">
<mdWrap MDTYPE="MODS">
<xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:role>
<mods:roleTerm type="text">advisor</mods:roleTerm>
</mods:role>
<mods:namePart>Handgretinger, Rupert (Prof. Dr.)</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Lamsfus Calle, Andrés</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2020-12-17T06:29:06Z</mods:dateAccessioned>
</mods:extension>
<mods:extension>
<mods:dateAvailable encoding="iso8601"/>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2020-12-17</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="other">1743106378</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10900/110762</mods:identifier>
<mods:abstract>β-hemoglobinopathies, including β-thalassemia and sickle cell disease&#xd;
(SCD), are autosomal recessive inherited disorders caused by various&#xd;
mutations in the β-globin gene. The most effective curative therapy involves&#xd;
allogenic hematopoietic stem cell transplantation (HSCT) from an&#xd;
immunologically-matched donor. However, this approach presents some&#xd;
limitations in terms of finding a suitable donor and transplantation related&#xd;
risks, such as a graft-versus-host disease (GvHD). In this thesis, we strongly&#xd;
emphasized that autologous HSCT in combination with gene therapy tools will&#xd;
develop novel treatments for β-hemoglobinopathies.&#xd;
A promising technique for gene editing has emerged in recent years based&#xd;
on the use of Clustered Regularly Interspaced Short Palindromic Repeats&#xd;
(CRISPR) -associated RNA-guided endonuclease Cas9 (CRISPR/Cas9)&#xd;
technology. This revolutionary tool enables to perform gene disruption, gene&#xd;
correction, and gene addition in a specific locus of interest with high reliability&#xd;
and efficiency. Through this technology, in our first study, we demonstrated&#xd;
that targeting KLF1 and BCL11A, which control the expression of γ-globin, as&#xd;
well as the promoter region of HBG1 and HBG2 (HBG1/2), resulted in upregulation&#xd;
of γ-globin gene expression and fetal hemoglobin (HbF).&#xd;
Furthermore, after a deep comparison between the three gene editing&#xd;
strategies, we confirmed that BCL11A approach, which is currently in clinical&#xd;
phase, is the safest gene therapy treatment for β-hemoglobinopathies.&#xd;
Nevertheless, HBG1/2 strategy also holds potential for clinical translation.&#xd;
Alternatively, since β-globin gene correction is also a feasible gene therapy&#xd;
approach, in our second study, we attained successfully gene addition in&#xd;
HSPCs by inserting a NheI-tag at the common aberrant splicing mutation&#xd;
point, HBB IVS1-110 by means of Cas9 mRNA and ssODN electroporation.&#xd;
In the last project, we thoroughly compared three lentiviral transgenes&#xd;
encoding for IGF2BP1, shRNA BCL11A, and ꝩ-globin to reactivate HbF&#xd;
production in HSPCs. Also, we assessed whether baboon envelope proteins&#xd;
(BaEV and BaEV-RLess) have a beneficial advantage over the regularly used&#xd;
vesicular-stomatitis-virus-G envelope protein (VSV-G). Our results showed&#xd;
4&#xd;
that all treatments using VSV-G envelope proteins resulted in therapeutic&#xd;
levels of HbF. In addition, baboon envelopes, especially BaEV-RLess,&#xd;
achieved decent levels of HbF with less viral particles, which might ameliorate&#xd;
the symptoms of the disease. Finally, even though IGF2BP1 and BCL11A&#xd;
approaches induced higher HbF levels than ꝩ-globin strategy, their role in&#xd;
gene regulation might cause undesired iatrogenic effects. Therefore, we&#xd;
considered ꝩ-globin the best lentiviral gene therapy strategy for the treatment&#xd;
of β-hemoglobinopathies.&#xd;
During this thesis we evidenced that both gene therapy tools, lentiviral&#xd;
gene transfer and genome editing, provide a successful platform for gene&#xd;
treatment of blood disorders. In addition to the current clinical trial&#xd;
approaches, we strongly believe that resurgence of HbF is the most straight&#xd;
forward strategy together with β-globin gene correction. However, due to the&#xd;
low occurrence of gene correction events in HSPCs, further investigation is&#xd;
required.</mods:abstract>
<mods:language>
<mods:languageTerm authority="rfc3066">en</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">ubt-podok</mods:accessCondition>
<mods:titleInfo>
<mods:title>Hematopoietic stem cell gene therapy for the treatment of β-hemoglobinopathies</mods:title>
</mods:titleInfo>
<mods:genre>PhDThesis</mods:genre>
</mods:mods>
</xmlData>
</mdWrap>
</dmdSec>
<amdSec ID="FO_10900_110762_1">
<techMD ID="TECH_O_10900_110762_1">
<mdWrap MDTYPE="PREMIS">
<xmlData xmlns:premis="http://www.loc.gov/standards/premis" xsi:schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>https://publikationen.uni-tuebingen.de/xmlui/bitstream/10900/110762/1/Lamsfus%20Calle%2c%20Andr%c3%a9s_PhD%20thesis.pdf</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>7a2f3dff40ab65e643bd7a7a51b5769c</premis:messageDigest>
</premis:fixity>
<premis:size>9678901</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>application/pdf</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>Lamsfus Calle, Andrés_PhD thesis.pdf</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<amdSec ID="FT_10900_110762_3">
<techMD ID="TECH_T_10900_110762_3">
<mdWrap MDTYPE="PREMIS">
<xmlData xmlns:premis="http://www.loc.gov/standards/premis" xsi:schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>https://publikationen.uni-tuebingen.de/xmlui/bitstream/10900/110762/3/Lamsfus%20Calle%2c%20Andr%c3%a9s_PhD%20thesis.pdf.txt</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>897ecbda875d6dbb0948757087b26349</premis:messageDigest>
</premis:fixity>
<premis:size>281664</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>text/plain</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>Lamsfus Calle, Andrés_PhD thesis.pdf.txt</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<fileSec>
<fileGrp USE="ORIGINAL">
<file ID="BITSTREAM_ORIGINAL_10900_110762_1" MIMETYPE="application/pdf" SEQ="1" SIZE="9678901" CHECKSUM="7a2f3dff40ab65e643bd7a7a51b5769c" CHECKSUMTYPE="MD5" ADMID="FO_10900_110762_1" GROUPID="GROUP_BITSTREAM_10900_110762_1">
<FLocat xlink:type="simple" LOCTYPE="URL" xlink:href="https://publikationen.uni-tuebingen.de/xmlui/bitstream/10900/110762/1/Lamsfus%20Calle%2c%20Andr%c3%a9s_PhD%20thesis.pdf"/>
</file>
</fileGrp>
<fileGrp USE="TEXT">
<file ID="BITSTREAM_TEXT_10900_110762_3" MIMETYPE="text/plain" SEQ="3" SIZE="281664" CHECKSUM="897ecbda875d6dbb0948757087b26349" CHECKSUMTYPE="MD5" ADMID="FT_10900_110762_3" GROUPID="GROUP_BITSTREAM_10900_110762_3">
<FLocat xlink:type="simple" LOCTYPE="URL" xlink:href="https://publikationen.uni-tuebingen.de/xmlui/bitstream/10900/110762/3/Lamsfus%20Calle%2c%20Andr%c3%a9s_PhD%20thesis.pdf.txt"/>
</file>
</fileGrp>
</fileSec>
<structMap TYPE="LOGICAL" LABEL="DSpace Object">
<div TYPE="DSpace Object Contents" ADMID="DMD_10900_110762">
<div TYPE="DSpace BITSTREAM">
<fptr FILEID="BITSTREAM_ORIGINAL_10900_110762_1"/>
</div>
</div>
</structMap>
</mets></metadata></record></GetRecord></OAI-PMH>